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Abstract
Background: Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected
individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear.
Methods: We used a simulation model of HIV testing and treatment to examine alternative HIV screening strategies: 1)
current practice, 2) one-time, 3) every five years, and 4) annually; and we applied these strategies to three population
scenarios: 1) the general Indian population (‘‘national population’’), i.e. base case (HIV prevalence 0.29%; incidence 0.032/
100 person-years [PY]); 2) high-prevalence districts (HIV prevalence 0.8%; incidence 0.088/100 PY), and 3) high-risk groups
(HIV prevalence 5.0%; incidence 0.552/100 PY). Cohort characteristics reflected Indians reporting for HIV testing, with a
median age of 35 years, 66% men, and a mean CD4 count of 305 cells/ml. The cost of a rapid HIV test was $3.33. Outcomes
included life expectancy, HIV-related direct medical costs, incremental cost-effectiveness ratios (ICERs), and secondary
transmission benefits. The threshold for ‘‘cost-effective’’ was defined as 3x the annual per capita GDP of India ($3,900/year of
life saved [YLS]), or for ‘‘very cost-effective’’ was ,1x the annual per capita GDP ($1,300/YLS).
Results: Compared to current practice, one-time screening was very cost-effective in the national population (ICER: $1,100/
YLS), high-prevalence districts (ICER: $800/YLS), and high-risk groups (ICER: $800/YLS). Screening every five years in the
national population (ICER: $1,900/YLS) and annual screening in high-prevalence districts (ICER: $1,900/YLS) and high-risk
groups (ICER: $1,800/YLS) were also cost-effective. Results were most sensitive to costs of care and linkage-to-care.
Conclusions: In India, voluntary HIV screening of the national population every five years offers substantial clinical benefit
and is cost-effective. Annual screening is cost-effective among high-risk groups and in high-prevalence districts nationally.
Routine HIV screening in India should be implemented.
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Introduction
India is home to one of the largest HIV epidemics in the world
with an estimated 2.3 to 2.5 million infected individuals [1]. The
national HIV prevalence is estimated to be 0.29%, though selected
regions and risk groups bear a substantially higher HIV burden
[2,3,4,5]. High prevalence regions include most southern Indian
states (.0.7%), while low prevalence regions include most
northern Indian states (,0.1%). Even within a high prevalence
state, such as Andhra Pradesh, multiple districts have an HIV
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prevalence greater than 20% [1,6]. National surveillance data also
demonstrate elevated HIV prevalence among high-risk groups,
including 8.7% among injection drug users (IDU), 5.7% among
men who have sex with men (MSM), and 5.4% among female sex
workers (FSW) [2].
Despite expanding access to antiretroviral therapy (ART) in
India, the majority of those infected are unaware of their HIV
status and hence unable to access lifesaving treatment [6,7,8,9].
Given the heterogeneity of the Indian HIV epidemic, current
screening guidelines developed by India’s National AIDS Control
Organization (NACO) emphasize increased HIV testing among
population subgroups identified as being at high risk for HIV
infection, specifically IDU, MSM, FSW, and migrants [10]. HIV
testing services have also expanded for the general population,
such that in the past five years, the number of public-sector HIV
voluntary counseling and testing (HIV-VCT) centers has nearly
doubled, to 5,135 sites across the country [1,11], with the goal to
test 22 million Indians by 2012 [10]. The expansion of HIV testing
is occurring in consort with increasing government-funded access
to ART and linkage-to-care programs [1]. Our objective was to
assess the clinical impact, cost, and cost-effectiveness of alternative
HIV screening strategies in India to provide decision makers with
an assessment of the implications of an expanded HIV screening
program.
Methods
Analytic Overview
We used the Cost-Effectiveness of Preventing AIDS Complica-
tions (CEPAC)-International model, a state-transition simulation
model of HIV detection and disease in resource-limited settings, to
project CD4 count at the time of HIV diagnosis, life expectancy,
HIV transmissions, cost, and incremental cost-effectiveness of
alternative HIV screening strategies in India. Details about the
model structure have been published elsewhere [12,13,14,15,16,
17,18]. Input parameters for the model included HIV prevalence
and incidence, test acceptance, linkage-to-care, HIV natural
history in the absence of treatment, treatment efficacy, and costs
of HIV testing, monitoring, and routine care. All data were from
India, when available. Life expectancy and costs were discounted
at 3% per year [19]. Sensitivity analyses examined uncertainties in
model parameters.
To determine the cost-effectiveness of each HIV screening
strategy, we adapted the general recommendations of the World
Health Organization (WHO) Commission on Macroeconomics
and Health, which categorize incremental cost-effectiveness ratios
(ICERs) ,3x the annual per capita Gross Domestic Product (GDP)
of a given country as ‘‘cost-effective’’, and screening strategies with
ICERs ,1x the per capita GDP of the country as ‘‘very cost-
effective’’ [20,21]. India’s per capita GDP in 2010 was $1,300 [20],
which translates to a threshold for ‘‘cost-effective’’ of ,$3,900/
year of life saved (YLS).
HIV Screening Strategies and Settings
We focused on the impact of HIV screening on the general
Indian population (i.e. base case), but also assessed two scenarios
targeting settings and groups at higher risk for HIV infection:
high-prevalence districts and high-risk groups. These three
screening scenarios with different underlying HIV prevalence,
incidence, and annual rate of ‘‘background’’ HIV testing (i.e.
current testing per year in the population, without an expanded
screening program) are concordant with classification schemes
employed by NACO: 1) national population (0.29% prevalence;
0.032/100PY incidence; 3.2% annual background screening); 2)
high prevalence districts (0.8% prevalence; 0.088/100PY inci-
dence; 3.3% annual background screening); and 3) high-risk
groups, including MSM, FSW, IDU, migrants, and STD clinic
attendees (5.0% estimated aggregate prevalence; 0.552/100 PY
incidence; 50% annual background screening) (Table 1) [22,23].
The comparison screening strategy in each scenario was the
current screening frequency in the respective population (i.e.
current practice), derived from the proportion of the population
that reports having had an HIV test in the past year (background
screening), as well as the proportion identified upon presentation
with an AIDS-defining OI [1]. For each scenario, we compared
three additional HIV screening strategies to current practice: one-
time, every five years, and annual screening. HIV-related cost and
life expectancy are reported both for the HIV-infected population
and for the entire population.
Disease Model
The CEPAC-International (CEPAC-I) model is a state-transi-
tion Monte Carlo simulation model of HIV disease and treatment
[14]. Each HIV-infected individual is followed from model entry
until death. The natural history of HIV disease is determined by
CD4 count decline, which depends on HIV RNA level [24]. HIV
morbidity (i.e. opportunistic infections [OIs]) and mortality are
CD4 count-dependent, with higher morbidity and mortality at
lower CD4 counts [25]. ART reduces HIV RNA levels, increases
CD4 counts, and decreases HIV-related morbidity and mortality
[26]. ART regimens follow guidelines from NACO and the WHO
[27,28,29]. ART-eligible individuals receive a first-line non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen
followed by a second-line regimen using a boosted protease
inhibitor (PI), if needed. HIV-infected individuals in care are
assumed to have CD4 count tests performed every 6 months; are
treated with co-trimoxazole prophylaxis at CD4 counts #200
cells/ml; receive the first of two sequential ART regimens once
their CD4 counts fall to ,350 cells/ml or after they develop a
WHO Stage III–IV disease; and are treated for any acute OIs that
develop [29]. In the absence of HIV RNA monitoring, detection
of treatment failure, based on observation of a 50% CD4 decline
from peak, a CD4 drop below pre-ART nadir, a CD4 count,100
cells/ml, or a severe OI while receiving ART, triggers a switch to
the second (and final) available ART regimen [27]. HIV-infected
individuals who are tested and linked-to-care, but not yet eligible
for ART, are assumed to be monitored with clinic visits every 3
months and CD4 counts every 6 months until their CD4 counts
are ,350 cells/ml. Once in care, HIV-infected individuals can be
lost to follow-up at a frequency consistent with observational data
from India, with the possibility of subsequently returning to care if
lost [30].
Screening Model
Entry into the disease model is determined by a population-level
screening model that includes HIV prevalence and incidence.
Further details about the Screening model can be found in
published reports [31,32]. Briefly, this model allows the user to
define cohort characteristics (e.g. distributions of age, sex, and, for
HIV-infected individuals, CD4 count, HIV RNA, and history of
OI). Given the demographic characteristics of HIV-uninfected
individuals and the user-defined incidence of HIV infection, the
model determines the number of incident HIV cases in the
simulation. In the model, individuals are offered an HIV test at a
specified screening frequency. Those who accept testing, based on
a user-defined probability of test acceptance, receive one rapid
HIV test; a reactive test triggers a confirmatory rapid test.
HIV Testing in India
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Table 1. Screening and disease model input parameters.
Variable Base case value
Range used in
sensitivity analyses Reference
Baseline cohort characteristics
Age, mean years +/2 SD at presentation 35+/25 [30]
Male sex (%) 66 [30]
HIV prevalence (%)
National population 0.29 0.15–0.44 [23]
High prevalence district 0.80 0.40–1.20 [22,40]
High-risk group 5.00 2.50–7.50 [23]
Annual incidence/100 person-years Model derivation
National population 0.032 0.016–0.048
High prevalence district 0.088 0.044–0.133
High-risk group 0.552 0.276–0.829
Distribution of initial CD4 count at model initiation,
mean cells/ml (SD)
Acute, primary HIV infection 553 (230) [58]
Chronic, HIV infection 305 (270) 50–350 [30,34]
HIV RNA distribution (%) [34]
.100,000 copies/ml 41
30,001–100,000 copies/ml 26
10,001–30,000 copies/ml 16
3,001–10,000 copies/ml 11
501–3,000 copies/ml 3
,500 copies/ml 4
HIV testing protocols
Rate of background HIV testing, % per year [1]
National population 3.2 0–6.4
High prevalence district 3.3 0–6.6
High-risk group 50 0–100
Sensitivity (%) 99.6 [10]
Specificity (%) 98.0 [10]
Test acceptance rate (%) 82 10–100 [40]
Linkage-to-care rate (%) 50 10–100 [43]
Loss-to follow-up (rate/100 PY) #1 year of ART initiation .1
year after ART initiation
11.7
5.8
[30]
Natural history of HIV disease
Mean monthly CD4 cell decline by HIV RNA level, cells/ml (SD) [24]
.30,001 copies/ml 6 (0.255)
10,001–30,000 copies/ml 5 (0.221)
3,001–10,000 copies/ml 5 (0.191)
501–3,000 copies/ml 4 (0.242)
,500 copies/ml 3 (0.251)
Percent monthly risk of severe opportunistic infectionsa [34]
Bacterial 0.0004–0.0022
Tuberculosis 0.0023–0.0597
WHO Stage 3–4 visceralb 0.0012–0.0338
WHO Stage 3–4 mucocutaneousc 0.0027–0.0478
Other WHO Stage IV defining
Illnesses
0.001–10.0229
Other severe infections 0.0023–0.0265
Percent monthly risk of mild opportunistic infections [34]
Bacterial 0.0022–0.0050
HIV Testing in India
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Individuals with undetected HIV infection in the Screening
model can be diagnosed via one of three mechanisms: 1)
background testing, which occurs at VCT sites, tuberculosis
clinics, STD centers, or antenatal clinics, based on current testing
patterns; 2) presentation with an AIDS-defining OI; or 3) an
expanded HIV screening program if available, as described in this
analysis. We define ‘‘current practice’’ as detection via mecha-
nisms 1 or 2. The analysis involves a conservative approach
towards expanded screening in which it is assumed that HIV
detection by ‘‘current practice’’ leads to successful linkage-to-care.
However, in the expanded screening programs, the rates of test
acceptance, test sensitivity and specificity, and linkage-to-care are
Table 1. Cont.
Variable Base case value
Range used in
sensitivity analyses Reference
Fungal 0.0032–0.0812
Other 0.0056–0.0271
Efficacy of co-trimoxazole (% reduction in probability of infection) [15]
Severe bacterial 49.81
Mild fungal infections 246.37d
Stage 3–4 visceralb 17.86
Mild bacterial 48.79
Other WHO Stage IV defining
Illnesses
17.88
Malaria 88.42
Efficacy of ART (% patients with HIV RNA suppression at 24 weeks)
First line (NNRTI +2 NRTIs) 73 63–83 [35]
Second line (PI +2 recycled NRTIs) 73 63–83 Assumption
Discount rate (%) 3 0–3 [19]
Costs
HIV testing and care costs ($, USD 2010)
Rapid HIV test, including Confirmatory test 3.33 0.5–2x base case [42]
Co-trimoxazole prophylaxis, Monthly 0.33 0.5–2x base case [18]
First-line ART, monthly 8.61 0.5–2x base case [59]
Second-line ART, monthly 55.12 0.5–2x base case [59]
Minor ART toxicity on first-line, monthlye 14.76 [60]
Major drug toxicity on first-line, monthlye 160.64 [60]
Routine care 7.23–24.74 0.5–2x base case [36]
Inpatient hospital care, per day 48.45 0.5–2x base case [36]
Outpatient hospital care, per visit 16.59 0.5–2x base case [36]
Acute OI event 24.89–175.77 0.5–2x base case [36]
CD4 test 6.54 0.5–2x base case [61]
HIV RNA test 47.96 0.5–2x base case [61]
Non-HIV care costs ($)
Overall health expenditure, monthly 2.88 0.5–2x base case [39]
Rate of HIV transmission according to plasma viral load, per 100
person-years
[45]
,500 copies/ml 0.16
500–3499 copies/ml 2.06
3500–9999 copies/ml 4.17
10000–49999 copies/ml 8.12
$50000 copies/ml 9.03
ART – antiretroviral therapy; WHO – World Health Organization; NNRTI – non-nucleotide reverse transcriptase inhibitor; NRTI – nucleoside reverse transcriptase inhibitor;
PI – protease inhibitor; OI – opportunistic infection; SD – standard deviation; PY – person-years; YLS – year of life saved.
aRange due to variation in probability of opportunistic infection acquisition depending on CD4 count.
bVisceral opportunistic infections include: Cryptococcal meningitis, PCP, toxoplasmosis, cryptosporidial diarrhea, parasitic diarrhea, encephalitis, CMV retinitis, non-
Hodgkins lymphoma, end stage renal disease, cancer of the vulva, Kaposi’s sarcoma, malignancy, and progressive multifocal leukoencephalopathy.
cMucocutaneous opportunistic infections include: esophagitis, esophageal candidiasis, oral hairy leukoplakia, and herpes simplex.
dNegative value reflects increased risk of developing mild fungal infections when taking co-trimoxazole.
eSee Text S1 for discussion of ART toxicity.
doi:10.1371/journal.pone.0064604.t001
HIV Testing in India
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Table 2. Base case results for an analysis of HIV screening in India.
HIV testing frequency
Current practice One-time Every 5 years Annually
National population
HIV-infected population
Mean CD4 count at detection (cells/ml)
Prevalent cases 201 290 289 312
Incident cases 314 314 383 464
Undiscounted per person life expectancy (months) a 285.1 291.0 307.6 331.6
Discounted per person life expectancy (months)a 184.2 188.5 196.1 208.2
Discounted per person costs ($) 1,137 1,385 1,843 2,597
Mechanism of HIV Detection (%)
Background screening 14 13 10 5
Presentation with opportunistic infection 14 14 10 4
Screening Program 0 7 34 74
Never detected 72 66 46 17
Overall population
Undiscounted per person life expectancy (months) 432.9 433.0 433.2 433.6
Discounted per person life expectancy (months) 253.6 253.7 253.8 253.9
Discounted per person costs ($) 739 745 762 818
Cost-effectiveness ratio ($/YLS) – 1,100 1,900 4,000
HIV testing frequency
Current practice One-time Every 5 years Annually
High prevalence district
HIV-infected population
Mean CD4 count at detection (cells/ml)
Prevalent cases 202 290 289 312
Incident cases 316 316 383 464
Undiscounted per person life expectancy (months) a 283.8 289.8 306.3 330.2
Discounted per person life expectancy (months)a 183.5 187.9 195.5 207.6
Discounted per person costs ($) 1,145 1,396 1,843 2,607
Mechanism of HIV Detection (%)
Background screening 14 13 10 5
Presentation with opportunistic infection 15 14 10 4
Screening Program 0 7 34 74
Never detected 71 66 46 17
Overall population
Undiscounted per person life expectancy (months) 427.9 428.2 428.8 429.7
Discounted per person life expectancy (months) 251.4 251.5 251.8 252.3
Discounted per person costs ($) 748 760 787 861
Cost-effectiveness ratio ($/YLS) – 800 1,100 1,900
HIV testing frequency
Current practice One-time Every 5 years Annually
High-risk group
HIV-infected population
Mean CD4 count at detection (cells/ml)
Prevalent cases 306 316 315 321
HIV Testing in India
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64604
user-specified. Only those who are tested for HIV, diagnosed,
linked-to-care, and meet eligibility criteria receive ART and OI
prophylaxis and accrue HIV-related costs of care. Those not yet
ART-eligible accrue only monitoring costs and non-HIV care
costs.
Disease Model Input Parameters
Cohort characteristics and disease progression. Baseline
cohort characteristics are from the national government HIV
testing program and the Y.R. Gaitonde Centre for AIDS Research
and Education (YRG CARE), a community-based tertiary care
facility in South India (Table 1) [30,33]. The mean age at
Table 3. Secondary transmission of HIV in the first 6 years following screening program implementation.
HIV testing frequency
Current
practice One-time Every 5 years Annually
National population
Prevalence 0.29%, Incidence 0.032/100PY, background testing 3.2% per year
Number of secondary cases (per 100,000) 6.92 6.75 6.65 6.19
Incremental HIV cases averteda (per 100,000) – 0.17 0.10 0.46
% incremental decrease – 2.5 1.5 6.9
High prevalence district
Prevalence 0.8%, Incidence 0.088/100PY, background testing 3.3% per year
Number of secondary cases (per 100,000) 6.99 6.82 6.72 6.26
Incremental HIV cases averteda (per 100,000) – 0.17 0.10 0.46
% incremental decrease – 2.4 1.5 6.8
High-risk group
Prevalence 5.0%, Incidence 0.552/100PY, background testing 50% per year
Number of secondary cases (per 100,000) 6.84 6.84 6.81 6.70
Incremental HIV cases averteda (per 100,000) – 0.0 0.03 0.11
% incremental decrease – 0.0 0.4 1.6
PY – person-years.
Transmission coefficient ranges from 0.16/100 PY to 9.03/100 PY depending on HIV RNA level [45].
aIncremental HIV cases averted relative to those averted with the next less frequent HIV testing strategy.
doi:10.1371/journal.pone.0064604.t003
Table 2. Cont.
HIV testing frequency
Current practice One-time Every 5 years Annually
Incident cases 467 467 475 496
Undiscounted per person life expectancy (months) a 316.2 318.8 320.3 324.5
Discounted per person life expectancy (months)a 200.6 202.4 203.2 205.5
Discounted per person costs ($) 2,554 2,669 2,720 2,893
Mechanism of HIV Detection (%)
Background screening 77 72 65 44
Presentation with opportunistic infection 4 4 3 2
Screening Program 0 8 17 44
Never detected 19 17 15 10
Overall population
Undiscounted per person life expectancy (months) 399.8 400.4 400.7 401.6
Discounted per person life expectancy (months) 239.1 239.5 239.7 240.2
Discounted per person costs ($) 1,116 1,143 1,162 1,235
Cost-effectiveness ratio ($/YLS) – 800 1,300 1,800
PY – person-years; YLS – year of life saved.
aCalculated from the time of model entry – includes time to HIV infection (incident cases only) and detection.
doi:10.1371/journal.pone.0064604.t002
HIV Testing in India
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Screening model entry is 35 (SD65) years [30]. Individuals with
undiagnosed prevalent HIV infection have a CD4 count and HIV
RNA distribution as reported for Indian cohorts [30,34]; the mean
CD4 count of chronically HIV-infected individuals in the cohort is
305 cell/ml (SD 270 cell/ml) [34], which is concordant with
internal calibration by the CEPAC-I model (See Text S1).
Data on HIV natural history and prophylaxis efficacy have been
published elsewhere [15,24]. The efficacy of first-line ART,
defined as HIV RNA suppression (,50 copies/ml) at 48weeks, is
73% [35]. Due to the absence of data on second-line ART efficacy
specifically from India, but consistent with the literature, we utilize
the same efficacy for second-line ART as for first-line ART [35].
Additional data on clinical inputs have been published in previous
India-based analyses [12,13,18]. For those enrolled in HIV care,
the rate of loss to follow-up from treatment is 11.7/100 PY for the
first 12 months on treatment and 5.8/100 PY thereafter [30].
Individuals lost to follow-up have a 50% probability of returning to
HIV care upon developing a WHO Stage III–IV OI or
tuberculosis.
Resource utilization and costs of care. Costs associated
with routine HIV care, acute HIV-associated OIs, and death are
derived using resource utilization data from the YRG CARE
observational database and a unit cost analysis [34,36]. ART drug
costs are from NACO [37]. Monthly per-person costs of first- and
second-line ART are $8.61 and $55.12, and the monthly cost of
co-trimoxazole prophylaxis is $0.33 [37,38]. Cost for an outpatient
visit is $16.59, and for an inpatient day $48.45 [36]. Non-HIV care
costs are applied monthly to both HIV-uninfected and HIV-
Figure 1. Impact of varying HIV incidence on the incremental cost-effectiveness of various testing frequencies. The incidence
(horizontal axis) was increased incrementally from 0 to 0.7/100 PY. The bold line indicates one-time screening compared with the current practice, the
dotted line indicates screening every five years compared with one-time screening, and the dashed line indicates annual screening compared with
screening every five years.The circle, triangle, and square indicate the base case incremental cost-effectiveness ratio for one-time screening compared
with the current practice, screening every five years compared with one-time screening, and annual screening compared with screening every five
years. The horizontal lines indicate the threshold values for ‘‘very cost-effective’’ (1x per capita India GDP) and ‘‘cost-effective’’ (3x per capita India
GDP).
doi:10.1371/journal.pone.0064604.g001
HIV Testing in India
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infected individuals, and are estimated at $2.88 per month, which
is the overall mean monthly health expenditure of Indian citizens
as estimated from population-level WHO data [39]. All costs are
standardized to 2010 US dollars using India’s GDP deflator [20].
Screening Model Input Parameters
HIV prevalence and incidence. We utilize HIV prevalence
data from NACO and the National Family Health Survey [23,40].
Due to lack of available HIV incidence data, we calculate annual
incidence estimates from the prevalence and model-derived
duration of infection (Text S1) [22,23,40].
HIV testing and outcomes. Based on data from the Indian
national testing program, the annual background testing rate is
estimated at 3.2% per year for the general population, but varies
by district and group [1,22,23,40]. Employing these estimates for
the national background testing rate and data from YRGCARE
on the mean CD4 count of ART-naı¨ve patients, we calibrate the
percentage of severe OIs (i.e. WHO Stage III and IV diseases and
tuberculosis) that trigger clinical detection of HIV to be 10%
[1,34], which is consistent with previous Indian estimates [18]. We
use a point-of-care HIV test (99.6% sensitivity and 98.0%
specificity), based on earlier Indian studies [10,41]. Reactive
results are confirmed by a second rapid test [10,42]. Test
acceptance (82%) is based on earlier Indian population-based
survey data [40]; and linkage-to-care frequency (50%) is based on
HIV testing at Indian TB clinics [40,43]. The cost of a rapid test is
$3.33, including both the confirmatory test for positives and the
salary of the counselor [42]. This cost is varied over a range of
values in sensitivity analysis (Text S1).
Secondary Transmission
Recognizing that expanded HIV screening and treatment at the
population level may have transmission benefits in addition to
individual clinical benefits, we project the number of secondary
incident HIV cases over six years (as a reasonable time span to
evaluate the public health impact given testing every 5 years was
being assessed as an intervention) [31,44]. HIV transmission rates
according to HIV RNA level, which vary from 0.16 per 100 PY
with HIV RNA ,400 copies/ml to 9.03 per 100 PY with HIV
RNA $50,000 copies/ml, are from a recent meta-analysis [45].
These rates are consistent with data on the impact of ART on
preventing HIV infection [46,47]. To estimate the number of
secondary HIV cases, we aggregate the number of person-years
spent by treatment-naı¨ve individuals at each HIV RNA level and
Figure 2. One-way sensitivity analyses: Screening every five years vs. one-time testing in the national population. The width of the
horizontal bars represents the difference in the incremental cost-effectiveness ratio ($/year of life saved, YLS) between the range described in
parentheses in the figure. The bold line represents the base case incremental cost-effectiveness ratio. The dashed line is the threshold value for ‘‘very
cost-effective’’ (1x per capita India GDP) and the dotted line is the threshold for ‘‘cost-effective’’ (3x per capita India GDP).
doi:10.1371/journal.pone.0064604.g002
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multiply by the corresponding HIV transmission rate. We then
sum the resulting number of transmissions at each HIV RNA level
to generate an overall estimate of secondary HIV transmission for
each screening strategy.
Sensitivity Analysis
We perform extensive univariate and multivariate sensitivity
analyses for each of the three population screening scenarios by
varying parameter values for HIV prevalence and incidence,
background HIV testing rates, test acceptance, linkage-to-care,
treatment efficacy and availability, and the costs of testing,
treatment, and care.
Results
National Population
Base case analysis. The mean CD4 count at diagnosis in the
national population ‘‘current practice’’ HIV screening strategy was
201 cells/ml for prevalent cases and 314 cells/ml for incident cases.
This increased to 290 cells/ml for prevalent cases with one-time
testing (no increase for incident cases) and to 312 cells/ml for
prevalent cases and 464 cells/ml for incident cases with annual
testing. The discounted life expectancy of HIV-infected individuals
from time of entry into the screening model was 184.2 months
(15.4 years; undiscounted 285.1 months, 23.8 years), and the
discounted life expectancy in the overall population was 253.6
months (21.1 years; undiscounted 432.9 months, 36.1 years;
Table 2). The addition of a one-time HIV screen at a mean age of
35 years increased discounted life expectancy to 188.5 months
(undiscounted 291.0 months) for HIV-infected individuals; for the
overall population, the discounted life expectancy increased to
253.7 months (undiscounted 433.0 months). Screening every five
years or annually increased the discounted life expectancy of HIV-
infected individuals to 196.1 and 208.2 months (undiscounted
307.6 and 331.6 months). As the HIV testing frequency increased,
more people were detected with HIV through screening programs,
in contrast to background screening or presentation with an
opportunistic infection (Table 2).
Expanded screening in the national population increased the
mean discounted per person lifetime cost of care from $739 for
current practice to $745, $762, and $818 for one-time, every five
years, and annual screening. Compared to current practice, one-
time screening had an ICER of $1,100/YLS. Screening every five
years resulted in an ICER of $1,900/YLS compared to one-time
screening. Screening annually resulted in an ICER of $4,000/YLS
compared to screening every five years.
Secondary transmission benefits. Under current screening
practice in the national population, we calculated over 6.92
secondary HIV transmissions per 100,000 people over a 6-year
period (Table 3). A one-time national population screen could
avert 2.5% of these secondary transmissions. Screening every five
years or annually could avert a further decrease of 1.5% and
6.9%.The number of HIV secondary transmissions could be
further reduced by improving test acceptance and linkage-to-care
rates, as well as improving viral suppression on ART (Tables S2
and S3).
Sensitivity analyses. While changes in HIV incidence and
prevalence had an impact on the ICER for screening, they did not
affect the policy conclusions substantially. Decreasing and
increasing HIV prevalence by 50% of the base case, with the
resulting change in derived incidence, yielded ICERs for national
screening every five years of $2,900/YLS and $1,500/YLS,
respectively (Table S1). As the incidence of HIV increased,
particularly above 0.2/100 PY, the ICER progressively dimin-
ished. Only when the incidence dropped below 0.03/100 PY did
the ICER for one time screening go above the 3x GDP threshold
(Figure 1).
In an additional one-way sensitivity analysis, linkage-to-care
rates, overall care costs, and HIV test costs had the greatest impact
on results (Figure 2). When the costs of ART, CD4 count and HIV
RNA monitoring, and non-HIV treatment costs were varied
individually, these parameters did not have a major impact on the
findings (Table S1).
In a two-way sensitivity analysis, we varied both the test
acceptance and linkage-to-care rates from 10% to 90%. Below
20% test acceptance and 20% linkage-to-care, national testing
every five years was no longer cost-effective.
High Prevalence Districts and High-risk Groups
Base case analysis. In high prevalence districts, with
background testing similar to the national population (3.3% per
year), one-time screening yielded an ICER of $800/YLS
compared to current practice (Table 2). Screening every five
years and annually yielded ICERs of $1,100/YLS and $1,900/
YLS.
Among high-risk populations, with a much higher reported
background testing rate (50% per year), one-time screening had an
ICER of $800/YLS relative to background testing (Table 2).
Screening every five years ($1,300/YLS) and annually ($1,800/
YLS) were both cost-effective. If the background testing rate was
decreased to 25%, one-time ($700/YLS), every five years ($1,000/
YLS), and annual screening ($1,200/YLS) became even more
attractive.
Secondary transmission benefits. We observed a preven-
tion impact of wider HIV screening in high-prevalence districts
similar to that in the national population. The proportion of
averted cases was lower in high-risk groups compared to high
prevalence districts, likely due to a higher frequency of reported
background testing, and thus earlier HIV diagnosis even without a
screening program implemented (Table 3).
Sensitivity analyses. In high prevalence districts and among
high-risk groups, decreasing the HIV prevalence by 50% still
yielded annual screening results well below the 3x per capita GDP
cost-effectiveness threshold (Figures S1 and S2). Annual testing
added cost with limited additional health benefits compared to
testing every five years. The results remained cost-effective when
all costs were doubled, even with annual testing.
Discussion
We modeled the impact of various HIV screening strategies in
India and found that screening every five years in the national
adult population would increase mean CD4 count at HIV
diagnosis, improve survival among the HIV-infected population,
modestly reduce secondary HIV infections at six years, and be
cost-effective by WHO criteria. We found that annual screening is
economically justifiable in specific sub-populations at increased
risk for HIV. Due to uncertainty over HIV prevalence and
incidence data in India, we varied these estimates widely. Even if
HIV prevalence was halved, screening every five years nationally,
and annual screening among high-prevalence districts and high-
risk groups, was still cost-effective when compared to a threshold
of 3x India’s annual per capita GDP ($3,900).
Previous studies have identified one-time, routine HIV screen-
ing to be cost-effective in many countries with a lower
undiagnosed HIV prevalence than in India, such as in the United
States and France [31,48,49]. In India, a majority of HIV-infected
individuals are unaware of their HIV status [1]. Clinical studies
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have documented that HIV-infected Indians continue to be
detected late in the course of their HIV disease, with 85%
registering for ART when their CD4 count is already ,250 cells/
ml [50]. Routine testing could detect HIV infection at an earlier
disease stage, link infected individuals to needed care, and
decrease the rate of secondary HIV transmission.
The findings of this study were robust across a wide range of
sensitivity analyses, including increasing HIV screening costs, as
well as treatment and monitoring costs. This suggests that
variations in programs by site, clinical services, or other
operational differences are unlikely to have a marked impact on
the overall findings. It is also likely that the costs of HIV screening
and disease management, including CD4 count and HIV RNA
monitoring, will continue to decrease based on the wider
utilization of new technologies in India [51,52]. Given limited
test acceptance and linkage-to-care following HIV detection, the
expansion of HIV screening services will need to occur in consort
with interventions aimed at improving both test acceptance and
developing better mechanisms of linking HIV-infected individuals
to treatment programs. Data from TB testing programs in India
that conduct HIV screening suggest that linkage-to-care remains
at only 50%; linkage is likely even worse among the Indian general
population [43]. In light of nationwide primary prevention
programs, such as the Gates Foundation-funded Avahan initiative,
which has averted an estimated 100,000 new HIV cases over five
years among high-risk groups residing in high prevalence Indian
states [53], it is possible that more Indians will seek HIV testing
and, for those found to be infected, will be linked-to-care.
When assessing the transmission benefits associated with
expanded HIV screening, this analysis suggests that ART-
associated reductions in HIV RNA could have an impact, albeit
relatively modest, over the short-term on reducing secondary
infections. Emerging data from resource-limited settings suggest
that accessing VCT is associated with a decrease in unprotected
sex [7,54,55,56]. This analysis did not account for the additional
prevention benefits associated with expanded testing. Additionally,
HIV-infected Indians also report decreased sexual risk behaviors
following enrollment in ART programs [57]. Recent clinical trial
data support the preventive impact of ART in reducing HIV
transmission among serodiscordant couples in resource-limited
settings [47]. By not changing the HIV incidence due to decreased
sexual risk behaviors over time, we aimed to generate conservative
estimates of projected life expectancy, cost-effectiveness, and
secondary cases averted of an HIV screening program.
There are several limitations to this analysis. The model
combines data from multiple sources to project the long-term
benefits of alternative HIV screening strategies. Disease progres-
sion parameters were from a tertiary care HIV center in South
India, but these clinical inputs were unlikely to be site-dependent;
demographic inputs were taken from the Indian government to
better reflect the characteristics of a national screening program.
Given limited HIV incidence data from India, HIV incidence
rates were estimated from back-calculations utilizing available
prevalence data [48]. To address the lack of population-level data
examining linkage-to-care and test acceptance in India, we
conducted sensitivity analyses to test the robustness of the results.
With the scale-up of ART, it is unclear whether district-level
testing facilities would be able to accommodate the increased
patient burden resulting from routine HIV testing. We did not
include a start-up cost for test sites that do not yet exist, but the
results were robust to test and care costs varied widely in sensitivity
analyses. In light of both logistical challenges as well as limited
funding, we adopted a conservative approach to provide decision
makers with a realistic assessment of the clinical impact and cost-
effectiveness of expanded HIV screening in India.
Routine HIV screening every five years is cost-effective in India
and should be implemented on a national, population-wide basis
to address the growing Indian HIV epidemic. More frequent
screening is warranted among Indian sub-populations with higher
HIV prevalence and incidence. This increased frequency of
testing, combined with the expansion of ART services, and recent
efforts towards earlier ART initiation, will improve outcomes in
those with HIV disease, decrease HIV transmission, and be cost-
effective in India.
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